Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Judy Muldawer who wrote (6029)	2/2/1999 9:25:00 AM
From: Patrick E.McDaniel	Read Replies (1) \| Respond to of 6136

Judy, nice news out today. biz.yahoo.com Pat

To: Judy Muldawer who wrote (6029)	2/2/1999 12:44:00 PM
From: Oliver & Co	Respond to of 6136

"Study Pinpoints 'Extremely Low Levels' of HIV" USA Today (02/02/99) P. 6D; Painter, Kim A study presented at the Sixth Conference on Retroviruses and Opportunistic Infections in Chicago showed that some people who were repeatedly exposed to HIV but do not appear to contract the virus are actually infected. The infected individuals--who had repeated, unprotected sex with infected partners, but continually tested negative for the virus--had "extremely low levels" of HIV, the researchers said. Tuofu Zhu, of the University of Washington at Seattle, said that the people may harbor defective HIV strains that do not cause disease but serve to protect them, similar to a natural vaccine, against more pathogenic strains.

To: Judy Muldawer who wrote (6029)	2/2/1999 12:45:00 PM
From: Oliver & Co	Respond to of 6136

"'Triple Cocktail' Hope in AIDS Fight" Financial Times (02/02/99) P. 10; Pilling, David New data suggest that triple-drug therapy without protease inhibitors is as effective in the suppression of HIV viral load as triple-drug therapies that contain them, according to the Atlantic study, which was conducted by European and U.S. universities. Protease inhibitors may have severe adverse effects, such as unusual fat deposits, in patients who take the drugs for long-periods of time. The results of the study were presented at an annual conference on retroviruses in Chicago.

To: Judy Muldawer who wrote (6029)	2/4/1999 10:48:00 AM
From: Henry Niman	Respond to of 6136

Judy, Speaking of AGPH, LGND, and BioCognizance, VRTX came out with a press release on Agenerase indicating that it did not affect lipid metabolism and retinoid signaling, although three PIs including Vircept did. Assays were in vitro and looked at PPARs and RXRs in addition to lipid metabolism. WLA of course has Rezulin which is a TZD that activates PPARs and they have an alliance with AGN that targets RXRs. The work was done by GLX, who of course had an alliance with LGND to look at lipid metabolism via PPAR/RXR signaling. The experiments used LGND's rexinoid, Targretin as wells as AGN's anti-retinoid. Details are linked to the anti-HIV page under New Therapeutics at biocognizance.com Thus, there could be some interesting intersections between PIs (represented by AGPH's Viracept) and lipid metabolism (represented by WLA's TZD, Rezulin, and AGN's rexinoids).

To: Judy Muldawer who wrote (6029)	2/5/1999 9:00:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 6136

Today's WSJ has an extensive review on HIV resistance. Details linked to anti-HIV table (which also has several reports from this week's conference) on New Therapeutics section of biocognizance.com